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Abstract 
Background: Poland introduced the 10-valent conjugate pneumococcal vaccine (PCV10) into the 
childhood immunization program in January 2017. During previous decades, considerable changes 
had occurred in the surveillance system for invasive pneumococcal disease. Therefore, to provide 
baseline data on pneumococcal diseases before PCV10 introduction, we evaluated the epidemiology 
of pneumococcal meningitis (PM), the only syndrome monitored consistently since 1970. 
 
Methods: Based on laboratory-confirmed cases reported during 2005-2015, we calculated the 
reported rates, serotypes distribution and antimicrobial resistance of pneumococcal meningitis 
isolates. Data from the mandatory national surveillance system was linked with data on 
cerebrospinal fluid isolates submitted to the National Reference Centre for Bacterial Meningitis. We 
used negative binomial regression with Newey West method to test for trend in rates of 
pneumococcal meningitis notified during 2005-2015 and Chi-squared test to assess changes in the 
serotype distribution from 2008-2011 to 2012-2015.  
 
Results: From 2005 to 2015, the overall reported incidence of PM increased from 0.21 to 0.47 cases 
per 100,000 population, average yearly increase of 7% (rate ratio 1.07; 95% CI 1.06-1.08). The 
increase was primarily due to annual increase of 3% (1.02-1.05) among 15-49 years of age, 12% (95% 
CI: 1.10-1.13) among 50-64 years of age, 18% (95% CI: 1.16-1.19) among persons 65-74 years of age 
and 9% (95%CI 1.07-1.10) among persons ≥75 years of age. In children <5 years of age, serotypes 
included in PCV10 and PCV13 accounted for 75% and 80% of reported isolates, respectively. From 
2008-2011 to 2012-2015, the proportion of PM cases caused by PCV10 serotypes decreased from 
52% to 41% (p<0.01). Overall, 28% of isolates were resistant to penicillin and 13% were non-
susceptible to cefotaxime. 
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Conclusions: The introduction of PCV10 into national immunization program may have considerable 
impact on disease burden, especially on number of cases caused by isolates non-susceptible to 
antimicrobials. 
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Background 
Streptococcus pneumoniae, along with Neisseria meningitidis and Haemophilus influenzae type b 
(Hib) [1–4], are most common causes of bacterial meningitis worldwide. In developed countries, case 
fatality for pneumococcal meningitis (PM) varies from 5% to 20% and sequelae such as hearing loss, 
seizures or focal neurological deficits occur in up to 50% survivors [1,5–7]. The disease affects mostly 
young children, the elderly and individuals with chronic illnesses [1]. Due to severity of the condition 
and established surveillance systems, PM is considered a reliable indicator of S. pneumoniae disease 
burden and long-term trends, allowing for international comparisons [8,9]. Epidemiology of 
pneumococcal meningitis has changed in many countries after implementation of seven- valent 
conjugate pneumococcal vaccine (PCV7), which later was replaced by 10- or 13-valent conjugate 
pneumococcal vaccines (PCV10, PCV13) [10–13]. The treatment of pneumococcal infections is 
complicated by increasing prevalence of clinical isolates of S. pneumoniae that are non-susceptible to 
first line antibiotics, primarily β-lactams [1,14]. The occurrence of non-susceptibility varies among 
countries, and may be as high as 40%-80% in certain geographic locations [15–18].  
In January 2017, Poland introduced PCV10 into the childhood immunization program. The vaccine is 
currently administered free of charge in a 2 + 1 schedule at 2, 4 and 13 months of age for children 
born after 1st January 2017. Before 2017, pneumococcal vaccines (PCV10, PCV13 and the 23-valent 
polysaccharide vaccine, PPSV23) were given free of charge only to children <5 years of age with risk 
factors. The indications included trauma or defects of central nervous system with cerebrospinal fluid 
(CSF) leakage, chronic heart failure, immunological-hematological diseases or HIV infection. In 
addition, some municipalities had organized vaccination at own cost for children registered as 
residents. In 2015, the vaccine uptake (including children with risk factors receiving any type of 
pneumococcal vaccine or vaccinated at the cost of their parents) was approximately 10% [19].   
Poland introduced mandatory surveillance of PM and other bacterial meningitis in 1970. The system 
is supervised by two institutions: the National Institute of Public Health- National Institute of Hygiene 
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(NIPH-NIH) and the reference laboratory - the National Reference Centre for Bacterial Meningitis 
(NRCBM).  In this system, physicians and laboratories report isolations of S. pneumoniae from 
normally sterile sites.  In our study, we analyzed baseline data on the epidemiology of pneumococcal 
meningitis before introduction of PCV10 into the childhood vaccination program in Poland. To 
provide data for evaluating the impact of PCV10 vaccination program in the future, the specific aims 
included assessing the reported rates, serotype distribution and antimicrobial resistance of 
pneumococcal meningitis isolates.  
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Materials and Methods 
 
Surveillance of pneumococcal meningitis  
In Poland, there are two independent passive surveillance systems for monitoring PM. The first 
system, based on mandatory reporting by physicians, is operated by NIPH-NIH. The second, 
consisting of voluntary reporting by laboratories is led by NRCBM.  In 2005, Poland implemented EU 
case definition for invasive pneumococcal disease (IPD) and extended the scope of reporting to other 
manifestations of IPD, than meningitis [20]. Physicians are obliged by law to notify to the local public 
health authority each suspect IPD case within 24 hours. Microbiological laboratories who isolate S. 
pneumoniae or detect S. pneumoniae nucleic acid from normally sterile site from patients also report 
to the local public health authority. Local public health authorities complete paper-based, 
standardized surveillance reports for each clinical case of PM and notify it bi-weekly to a population-
based surveillance system coordinated by the NIPH-NIH. Multiple notifications with the same 
identification information (name, surname, address, place of hospitalization) are merged into one 
case, if they refer to the same illness episode.  
Laboratory-based surveillance of PM since 1997 is operated by the NRCBM which receives clinical 
materials for PCR, the pneumococcal isolates, performs serotyping, and tests antimicrobial 
susceptibility of isolates. Data on demographic characteristics, antibiotic therapy, vaccination status, 
clinical symptoms, and the disease outcome, if already available, are collected for all isolates. 
Since 2010, data from the NIPH-NIH and the NRCBM have been linked by using identification 
information and submitted to the European Surveillance System (TESSy) maintained by the European 
Centre for Disease Prevention and Control (ECDC). Notifications of materials and isolates, which were 
sent to the NRCBM but not reported to the NIPH, are actively collected as part of an enhanced 
surveillance. The schematic presentation of surveillance systems of pneumococcal meningitis is 
depicted in the Graph 1. 
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Data sources 
Data on number of cases, their demographics (age, sex), outcome of the disease and districts where 
cases were reported, were collected from the population-based surveillance database coordinated 
by the NIPH-NIH. Year of notification was acquired from the date of onset of symptoms or, if 
unavailable, specimen collection date. After linkage with the NRCBM databases (based on 
identification information), data on serotypes and antimicrobial susceptibility of those cases was 
collected. 
 
Study design  
We performed an observational, population-based study. The study population consisted of all 
residents living in Poland between 1 January 2005 and December 2015.  
 
Case definition 
We defined a case of pneumococcal meningitis as isolation of S. pneumoniae from CSF during 2005-
2015 and notified to the NIP-NIH.  
 
Reported rates and trend 
Data were stratified into seven age groups (<1 year, 1-4 years, 5-14 years, 15-49 years, 50-64 years, 
65-74 years, ≥75 years). Annual, age-specific and district-specific reported rates per 100,000 were 
calculated using data from the Central Statistical Office as denominators.  
To test trend in rates during 2005-2015 and correct for overdispersion of data, we used negative 
binomial regression. To adjust for autocorrelation, we used Newey West method. Rate ratios (RR), 
their 95% confidence intervals (CI) and p-values for yearly changes were calculated using time (year) 
as a continuous explanatory variable in the model.  
 
 
 8 
Case fatality proportion 
We calculated case fatality proportion (CFP) by age group as a number of cases resulting in death, 
divided by all reported cases. To assess changes in CFP between 2005-2010 and 2011-2015, we used 
chi-square test; p-value <0.05 was considered statistically significant. 
 
Serotype distribution and diversity 
We calculated proportions of S. pneumoniae isolates by vaccine- serotypes. The 10-valent 
pneumococcal conjugate vaccine contains serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F; the 13-
valent pneumococcal conjugate vaccine adds serotypes 3, 6A, and 19A. Those three additional 
serotypes were defined as PCV13 - PCV10. The 23-valent pneumococcal polysaccharide vaccine 
contains 12 serotypes in common with PCV13 and 11 unique serotypes (2, 8, 9N, 10A, 11A, 12F, 15B, 
17F, 20, 22F, 33F). The non-vaccine types were categorized as non-PCV10 and non-PCV13. Serotypes 
15B and 15C were grouped together as 15B/C because of the reported reversible switching between 
these serotypes, which makes differentiation difficult [21]. We used chi-squared test to assess 
changes in the serotype distribution between 2008-2011 and 2012-2015. 
To assess the diversity of reported serotypes, we used the Simpson’s index of diversity (D) [22]. D 
refers to the probability that two randomly selected isolates have different serotypes. We defined D 
as:  
𝐷𝐷 = 𝑁𝑁(𝑁𝑁 − 1)  ×  �1−��𝑛𝑛𝑖𝑖𝑁𝑁�2 𝑚𝑚
𝑖𝑖=1
� 
 
where, N is the total number of pneumococcal meningitis cases (sample size), n is the number of 
cases with serotype i, m is the total number of serotypes [23].  
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Serotyping 
S. pneumoniae CSF isolates sent to the NRCBM were serotyped using Pneumotest-Latex kit (Statens 
Serum Institut, Copenhagen, Denmark), PCR or sequencing. Serotypes not identified by the above 
methods were subjected to the Neufeld Quellung test in the Statens Serum Institut in 2008, and in 
the National Reference Center for Streptococci in Aachen, Germany in 2009-2015, as previously 
described [24]. 
 
Antimicrobial susceptibility  
Minimal inhibitory concentrations (MICs) for penicillin and cefotaxime were determined by the Etest 
(AB Biodisk-bioMérieux) or MICEvaluators (Oxoid-Thermo Fisher) according to manufactures 
instructions.  
For the interpretation of MICs data, the EUCAST 2015 breakpoints for meningitis cases were applied 
[25]. Pneumococcal meningitis isolates were categorized as susceptible (S), intermediate (I), and 
resistant (R). The intermediate and resistant isolates were collectively referred to as non-susceptible. 
 
Data analysis 
All analyses were done with STATA version 13 (STATA Corp., Texas, USA) and Microsoft Excel 2013. 
 
Ethical considerations 
Data used in the analysis were collected as a part of national routine surveillance activities which fall 
under the existing mandate of the NIPH-NIH and the NRCBM. No formal approval of Institutional 
Review Board was required for this non-interventional study [26]. Identification data (names, 
addresses) were removed after matching with vital status or serotype. 
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Results 
Descriptive analysis  
From January 2005 until December 2015, a total of 1435 cases of pneumococcal meningitis were 
notified to the NIPH-NIH. Information on age was available for 1432 (99.8%) cases. The median age 
of cases was 48 years (interquartile range (IQR), 25-60 years), and 63% (910/1435) were male. 
Fourteen percent (200/1432) of cases were in children under 5 years of age and 16% (226/1432) 
were adults ≥ 65 years. The overall case fatality proportion was 20% (281 deaths) and varied from 4% 
(4/90) in children under 1 year of age to 31% (71/226) in people ≥ 65 years of age. Most of the 
deaths occurred within 30 days of symptom onset (81%, 228/281). The CFP was higher in 2005-2010 
(22%) than in 2011-2015 (18%) (p=0.052). 
 
Reported rates of pneumococcal meningitis and trends 
The highest rate was among children under 1 year of age, followed by 1-4 years of age and people 
65-74 years of age (Table 1). The reported rates in the youngest age group were characterized by 
substantial variation, from 0.52 cases per 100,000 person-years in 2007 to 3.59 cases per 100,000 
person-years in 2010. The overall rate increased steadily from 0.21 cases per 100,000 person-years in 
2005 to 0.47 cases per 100,000 person-years in 2015. This represented an average increase by 7% 
per year (RR 1.07, 95% CI: 1.06-1.08), primarily due to annual increase by 3% (1.02-1.05) among 15-
49 years of age, 12% (95% CI: 1.10-1.13) among 50-64 years of age, 18% (95% CI: 1.16-1.19) among 
persons 65-74 years of age and 9% (95%CI 1.07-1.10) among ≥75 years of age. Trends in other age 
groups were not statistically significant (Table 1). Male to female rate ratio was 1.85 (0.45 
cases/100,000 person-years vs. 0.24 cases/100,000 person-years). There were geographical 
differences in the reported rates notified in 2005-2015, ranging from 0.18 cases per 100,000 person-
years in district 10, to 0.52 cases per 100,000 person-years in district 11 (Figure 1). The reported rate 
was higher in urban areas, than rural (0.38 cases per 100,000 person-years and 0.28 cases per 
100,000 person-years, respectively).  
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Serotype distribution of pneumococcal meningitis isolates 
Of the 1149 PM cases reported to the NIPH-NIH in 2008-2015, 676 (59%) CSF isolates were sent to 
the NRCBM. The proportion of isolates sent to the NRCBM varied from 49% in 2008 to 67% in 2015. 
Of the 676 isolates available for serotyping, 672 belonged to 48 different serotypes or serogroups; 4 
isolates were non-typeable. The most common serotypes were 3 (71 isolates, 11% of all isolates), 19F 
(65, 10%), 14 (58, 9%) and 23F (40, 6%). There were no significant differences in serotype distribution 
between 2008-2011 and 2012-2015, except an increase in serotype 19A (increase from 2% in 2008-
2011 to 6% in 2012-2015, p= 0.0106) and 23B (from 0% to 3%, p= 0.0027). The serotypes present in 
PCV10, PCV13 and PPSV23 accounted for 46% (309/676), 62% (419/676) and 83% (563/676) of all 
isolates, respectively. Between 2008-2011 and 2012-2015, there was significant decrease in the 
proportion of cases caused by PCV10 serotypes, from 52% to 41% (p= 0.0044), respectively. There 
were no significant changes in proportions of PCV13 (p= 0.0630) and PPSV23 (p= 0.0848), PCV13-
PCV10 (p= 0.1622) and PPSV23 unique serotypes (p= 0.5409). 
Among serotypes identified at least 20 times during the study period, the highest CFP was found for 
serotype 4 (34%, 12 deaths/35 isolates), 8 (29%, 6/21), 22F (29%, 6/21) and 10A (22%, 5/23). 
However, the observed differences in CFPs were not statistically significant. 
 
Of the 112 isolates notified in children under 5 years of age, most common were serotypes 14 (n=23, 
21%), 19F (n=22, 20%), 6B (n=14, 13%), 23F (n=9, 8%), 9V (n=6, 5%) and 15B/C (n=5, 5%) (Table 2). 
There were no significant changes in frequency of particular serotypes between 2008-2011 and 
2012-2015. PCV10, PCV13 and PPSV23 serotypes accounted for 75% (84/112), 80% (90/112) and 93% 
(104/112) of isolates, respectively. Comparing the distribution of serotypes in 2008-2011 to 2012-
2015, the proportion of PCV10 serotypes declined from 87% to 57% (p= 0.0004); PCV13 serotypes 
decreased from 91% to 64% (p= 0.0003), PPSV23 serotypes decreased from 96% to 89% (p= 0.1511) 
and the proportion of non-PCV10 serotypes increased from 13% to 43% (p= 0.0004), non-PCV13 from 
9% to 36% (p= 0.0003) and PCV13-PCV10 serotypes from 4% to 7% (p= 0.4860).  
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Among individuals ≥5 years of age (564 isolates), the most common were serotypes 3 (n=70, 12%), 
19F (n=43, 8%), 14 (n=35, 6%), 4 (n=33, 6%), 23F (n=31, 6%) and 19A (n=27, 5%) (Table 3). PCV10, 
PCV13 and PPSV23 serotypes accounted for 40% (225/564), 58% (329/564) and 81% (459/564) of 
isolates, respectively. There were no significant changes in proportion of PCV10, PCV13 or non-
PCV10, non-PCV13 and PCV13-PCV10 serotypes between 2008-2011 and 2012-2015. 
Simpson’s index of diversity was 0.894 and 0.954 in children < 5 years of age and individuals ≥5 years, 
respectively. 
 
Antimicrobial susceptibility 
Data for antimicrobial susceptibility were available for 670 pneumococcal meningitis isolates (99.1%) 
reported in 2008-2015. Overall, 28% (189/669) of isolates were resistant to penicillin (MIC >0.06 
mg/L). There was no significant change in the frequency of penicillin resistant isolates reported in 
2008-2011 and 2012-2015 (29% and 27% respectively, p = 0.5671). Resistance to penicillin was 
common among serotypes 19A (26/29, 90%), 9V (19/24, 79%), 19F (47/65, 72%), 14 (40/58, 69%) and 
6B (23/35, 66%). Among children <5 years of age, 53% (58/110) of the isolates were resistant to 
penicillin compared with 23% among persons  ≥ 5 years of age (p<0.0001). Serotypes with high 
proportion of penicillin resistance were: 19A (2/2, 100%), 9V (6/6, 100%), 23B (1/1, 100%), 19F 
(18/22, 82%), 14 (16/23, 70%), 6A (2/3, 67%) and 23F (5/9, 56%). 
Isolates with decreased susceptibility to cefotaxime (MIC >0.5 mg/L) constituted 13% (90/670) of 
isolates tested in 2008-2015. The frequency of cefotaxime non-susceptibility did not change 
significantly between 2008-2011 (14%) and 2012-2015 (13%) (p = 0.7066). Non-susceptibility to 
cefotaxime was highest among isolates of serotypes 19A (17/29, 59%), 35B (1/2, 50%), 19F (30/65, 
46%), 14 (25/58, 43%), 23F (10/40, 25%) and 9V (5/24, 21%). Among children < 5 years of age, 22% 
(24/110) of isolates were non-susceptible to cefotaxime compared with 12% among persons  ≥5 
years of age (p = 0.0052). The highest proportion of cefotaxime non-susceptible isolates was 
identified in serotypes 19A (2/2, 100%), 23 F (4/9, 44%), 14 (10/23, 43%) and 19F (8/22, 36%). 
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Discussion 
Our study described comprehensive 10-year baseline epidemiologic characteristics of PM cases 
reported to the national surveillance system (NIPH-NIH) in Poland before the introduction of 
universal PCV10 vaccination. To date, the analysis of epidemiology of PM was conducted only by the 
NRCBM and was limited to submitted isolates. There was an increasing trend in reported rates of 
pneumococcal meningitis, primarily among persons older than 15 years. During the study period 
almost half of the cases were caused by PCV10 serotypes. The average penicillin resistance of isolates 
was significantly higher among children less than 5 years of age and higher than in most European 
countries.  
 
The age distribution of reported cases in Poland was similar to that notified in other European 
countries, with children below 5 years of age and persons ≥ 65 years of age having highest reported 
rates. Although the rates observed in our study (average 0.34 cases per 100,000 person-years) were 
higher than in the previous Polish studies [27,28], the overall and age-specific rates were 
considerably lower than those reported from other countries before introduction of pneumococcal 
conjugate vaccines, such as Finland [29], the Netherlands [30], England and Wales [31], Austria [32] 
or USA [10]. The low rates for pneumococcal meningitis in Poland may be due to low surveillance 
sensitivity or frequent administration of antibiotics immediately after clinical diagnosis or suspicion 
of meningitis, resulting in negative culture results [28]. The largest differences in reported rates 
between Poland and other European countries were among the elderly, suggesting considerable 
underreporting in this age group. This hypothesis is supported by the findings from the prospective 
study conducted in 124 pediatric hospitals or wards in five randomly selected districts in Poland 
during 2003-2004 [33]. The rates of pneumococcal meningitis were estimated to be 3.8 cases/ 
100,000 person-years in children < 5 years of age and 4.1 in children <2 years of age, respectively. 
The study showed that 108 out of 134 cases of laboratory-confirmed invasive pneumococcal disease 
were culture-negative and therefore serotyping data was available for 26 isolates only. Additionally, 
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28% children were treated with antibiotics before blood or CSF sampling. Relatively low reported 
rates should be taken into account when designing future vaccine effectiveness or impact studies or 
conducting evaluations of the economic and health benefits of the PCV10 vaccination program. 
Underestimated burden of meningitis will affect the absolute number of cases prevented/reduced 
after conjugate vaccine introduction.  
 
The increasing rates of pneumococcal meningitis from 0.21 cases per 100,000 person-years in 2005 
to 0.47 cases per 100,000 person-years in 2015 may reflect changes and systematic improvements in 
the surveillance system for IPD. Historically, epidemiological surveillance of IPD in Poland was limited 
to meningitis cases, which have been routinely reported by physicians since 1970. The 
implementation of EU case definition for IPD in 2005 [20], allowed collection of data on whole 
spectrum of clinical manifestations of IPD and thus improved surveillance sensitivity. In addition, 
active searching of cases reported to the NRCBM but not reported to the NIPH, increased the 
number of reported cases included in the national surveillance data. The significant increase in rate 
was reported primarily among persons ≥15 years of age. This may be related to better case 
ascertainment and reporting in this age group. However, influence of secular trends cannot be 
excluded. The reason for the substantial variation in reported rates in children <1 years of age, 
between 2007 (0.5 cases per 100,000 person-years) and 2010 (3.59 cases per 100,000 person-years) 
is unknown, since there were no outbreaks reported. During the study period, changes in reported 
rates among children < 15 years of age were not statistically significant. This might be related to 
small number of cases, fluctuations in reported rates which affect the possibility to observe linear 
trend, or to other factors.  
 
Changes in clinical practice also might have influenced the increased number of observed cases. 
However, in Poland, as in most European countries, cerebrospinal fluid (CSF) collection is a standard 
procedure in suspected pneumococcal meningitis [34]. Thus, epidemiology of PM is likely to be less 
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affected by changes in clinical practice than IPD incidence where blood culturing practices for 
diagnosis of pneumonia can influence observed rates [9,35]. Taking into account changes in 
surveillance system, the data on observed trends should be interpreted with caution.  
 
The observed lower CFP in 2011-2015 comparing to 2005-2010, might be related to better 
surveillance, since more cases with less severe disease could have been reported. In addition in 2011, 
the national guidelines for diagnostic and treatment of bacterial meningitis were edited under 
umbrella of the National Programme for Antibiotic Protection by the National Medicines Institute 
[34]. 
 
The serotype distribution of pneumococcal meningitis isolates was characterized by considerable 
heterogeneity, especially among persons ≥5 years of age. Higher heterogeneity in older age groups 
has also been observed in other countries [36]. As in other countries before implementation of 
vaccination, the most common serotypes in children were 14, 19F, 23F [37,38]. In adults, serotype 3 
was most common. Findings from other studies indicated that serotype 3 is commonly isolated in 
meningitis and associated with unfavorable outcomes [39]. The highest CFPs were reported for 
serotypes 4, 8, 22F and 10A. In a Danish nationwide population-based study, serotypes 4, 8, 22F were 
also found to be associated with higher 30-day mortality in meningitis patients [40]. There was 
significant increase in the proportion of serotype 19A and 23B reported in 2012-2015, compared 
with 2008-2011. In children < 5 years of age, the most common were serotypes 14 and 19F. Both 
serotypes are targeted by available vaccines. In children <5 years of age, serotypes targeted by 
PCV10 and PCV13 accounted for higher proportion of all reported isolates, than in individuals  ≥5 
years of age. However, in children < 5 years of age, proportion of PCV10 and PCV13 serotypes 
decreased significantly from 2012-2015 to 2008-2010.  It is difficult to assess the impact of local 
vaccination programs on the rise in non-PCV serotypes, because detailed data on vaccine coverage in 
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specific time and regions were unavailable. These results indicate high potential for prevention of 
meningitis cases by PCV10, PCV13 and PPSV23 vaccines.  
 
A number of studies have documented a significant decline in the reported rates of PM in the PCV 
vaccinated children. Some studies have shown the decrease in incidence also in older children and 
adults not targeted by vaccine, through herd effect. However, decrease in incidence due to the 
vaccine serotypes resulted in an increase in PM caused by non-vaccine serotypes [23].  In countries 
where PCV7 or PCV10 has been used in the infant vaccination programs, number of serotype 19A 
cases has increased both in children and adults, becoming one of the most common cause of 
meningitis. In contrast, after implementation of infant PCV13, the number of serotype 19A cases 
decreased significantly among both vaccinated and unvaccinated population groups [41]. However, 
increases in proportion of a wide variety of non-PCV13 serotypes have been seen after PCV13 
introduction. In Germany, a significant increase in percentage of serotypes 12F, 15C, 22F, 23B and 
35B was observed in children, after PCV introduction. In adults, increases in percentage of serotypes 
6C, 12F, 15B, 22F, 23A, 23B and 35B were observed [42]. In France, after PCV13 introduction increase 
in frequency of serotypes 12F, 24F, 23B, 10A, 15A and 6C was observed [43]. However, results of 
herd effect and serotype replacement were not consistent in all countries. To allow assessment of 
changes in serotype distribution and potential serotype replacement in Poland, ongoing surveillance 
on circulating strains is essential. 
 
The average penicillin resistance of isolates amounted 28% and was significantly higher among 
children less than 5 years of age. There were no substantial changes in penicillin resistance during 
the study period. Poland along with Romania, Malta and Iceland, has one of the highest proportion 
of IPD isolates resistant to penicillin. In Europe there is wide variation in antimicrobial susceptibility 
of pneumococcal isolates [44]. Differences are likely related to diversity in circulating strains, 
antibiotic use, vaccination policy, diagnostic capacity and access to healthcare. In our study, most of 
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penicillin resistant isolates were targeted by PCV13. Several studies have demonstrated that 
vaccination with pneumococcal conjugate vaccines (PCV7, PCV10 and PCV13) reduced the 
nasopharyngeal carriage of penicillin-resistant S. pneumoniae and thus pneumococcal resistance in 
vaccinated and unvaccinated population [45–47]. Prevention is especially important since 
antimicrobial resistance has been associated with worse clinical outcomes in patients with 
pneumococcal meningitis [48].   
 
In addition to low sensitivity, the surveillance system for pneumococcal meningitis in Poland has 
several other limitations. Our study shows substantial regional variation in reported rates. This 
suggests considerable underreporting in some districts (district 10, 3, 6, 13) and important areas for 
improvement. In addition, during 2008-2015 less than 60% of isolates reported to the NIPH-NIH were 
sent to the NRCBM and serotyped. Formal evaluation of the surveillance system should be 
performed before conducting vaccine effectiveness or impact studies. This is especially important 
because of the planned change from paper-based to electronic based reporting surveillance system. 
Changes in surveillance can affect sensitivity of surveillance and quality of surveillance data. Media 
attention for pneumococcal disease after introduction of PCV10 could possibly improve awareness of 
IPD and result in further increase in the number of reported cases.   
 
The strength of the study is a population-based design and all residents are entitled to free acute 
healthcare. Pneumococcal meningitis is a severe and life-threatening condition, thus each case is 
hospitalized. However, several limitations of this study should be noted. In the analysis only CSF 
culture-confirmed cases were included. Cases diagnosed on the basis of other laboratory methods 
such as PCR or antigen detection from CSF or blood culture with clinical symptoms of meningitis, 
were excluded from the study. This may have led to underestimation of the number of cases. The 
trend in reported rates was probably affected by the matching of cases captured by the two 
surveillance systems, initiated in 2010. However, the separate analysis of cases passively reported 
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only was not possible due to lack of register of actively collected cases in 2010-2014, and thus 
different form of reporting. Since the outcome of the disease was collected by the public health 
authority, there is a possibility that some fatal cases were not captured, if the death occurred after 
the collection of the data or the patients was moved to another hospital. 
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Conclusions 
This is the first study assessing long term trends of pneumococcal meningitis cases reported to 
mandatory surveillance system in Poland. The reported incidence of pneumococcal meningitis 
increased in persons ≥15 years of age. In children <5 years of age, serotypes included in PCV10 and 
PCV13 accounted for 75% and 80% of reported isolates, respectively. The introduction of PCV10 into 
national immunization program may have considerable impact on disease burden, especially on 
number of cases caused by isolates non-susceptible to antimicrobials. 
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Graph 1. Surveillance system of pneumococcal meningitis in Poland 
 
 
 
 
NRCBM- National Reference Centre for Bacterial Meningitis; NIPH-NIH- National Institute of Public Health- National 
Institute of Hygiene; TESSy- The European Surveillance System.  
Blue line- standard surveillance; Green line- Enhanced surveillance 
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Table 1. Rates and number of cases of pneumococcal meningitis according to age group (years) and mean annual relative change in incidence, 2005-2015, 
Finland 
 
  
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2005-2015 % Change* (95%CI) 
<1 1.94 (7) 1.64 (6) 0.52 (2) 1.94 (8) 2.12 (9) 3.59 (15) 2.77 (11) 1.56 (6) 3.26 (12) 2.18 (8) 1.66 (6) 2.12 (90) 4 (-2 to 10) 
1-4 0.35 (5) 0.56 (8) 0.77 (11) 0.68 (10) 0.53 (8) 0.77 (12) 1.20 (20) 0.60 (10) 0.36 (6) 0.45 (7) 0.85 (13) 0.65 (110) 3 (-1 to 8) 
5-14 0.24 (11) 0.14 (6) 0.29 (12) 0.25 (10) 0.31 (12) 0.21 (8) 0.29 (11) 0.13 (5) 0.27 (10) 0.26 (10) 0.21 (8) 0.24 (103) -1 (-3- to 0) 
15-49 0.14 (27) 0.18 (35) 0.26 (51) 0.20 (38) 0.24 (47) 0.23 (44) 0.22 (42) 0.16 (30) 0.32 (60) 0.20 (38) 0.29 (54) 0.22 (466) 3 (2 to 5) 
50-64 0.32 (22) 0.34 (24) 0.29 (22) 0.40 (31) 0.40 (31) 0.46 (37) 0.69 (57) 0.47 (39) 0.67 (55) 0.77 (62) 0.72 (57) 0.51 (437) 12 (10 to 13) 
65-74 0.20 (6) 0.17 (5) 0.32 (9) 0.22 (6) 0.54 (15) 0.44 (12) 0.33 (9) 0.53 (15) 0.94 (28) 0.47 (15) 0.92 (31) 0.47 (151) 18 (16 to 19) 
≥75 0.14 (3) 0.27 (6) 0.30 (7) 0.13 (3) 0.34 (8) 0.20 (5) 0.28 (7) 0.35 (9) 0.31 (8) 0.34 (9) 0.37 (10) 0.28 (75) 9 (7 to 10) 
TOTAL 0.21 (81) 0.24 (90) 0.30 (114) 0.28 (106) 0.34 (130) 0.35 (133) 0.41 (157) 0.30 (114) 0.46 (179) 0.39 (149) 0.47 (179) 0.34 (1432) 7 (6 to 8) 
 
* Mean annual relative change in incidence calculated by negative binomial regression with Newey West method 
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Table 2. Serotypes distribution (%) of pneumococcal meningitis isolates among persons <5 years of 
age reported to the NIP-NIH, 2008-2015, Poland 
  
2008 2009 2010 2011 2012 2013 2014 2015 2008-2015 
NO. OF CASES REPORTED 
TO THE NIP-NIH 
18 17 27 31 16 18 15 19 161 
NO. AND PROPORTION (%) 
OF ISOLATES SENT TO THE 
NRCBM AND SEROTYPED 
15 (83) 13 (76) 19 (70) 21 (68) 9 (56) 13 (72) 10 (67) 12 (63) 112 (67) 
NO. OF DIFFERENT 
SEROTYPES 
8 6 7 8 9 9 8 8 25 
SIMPSON D' INDEX 0.914 0.821 0.860 0.838 1.000 0.923 0.956 0.939 0.894 
PCV10/PCV13 SEROTYPES 
         
1 0.0 0.0 0.0 0.0 0.0 7.7 0.0 0.0 0.9 
4 0.0 0.0 0.0 4.8 0.0 0.0 10.0 0.0 1.8 
5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
6B 20.0 7.7 21.1 9.5 11.1 7.7 0.0 16.7 12.5 
7F 13.3 7.7 0.0 0.0 0.0 0.0 0.0 0.0 2.7 
9V 0.0 0.0 5.3 19.0 11.1 0.0 0.0 0.0 5.4 
14 13.3 23.1 26.3 33.3 0.0 23.1 20.0 8.3 20.5 
18C 6.7 15.4 0.0 0.0 11.1 0.0 0.0 0.0 3.6 
19F 6.7 38.5 21.1 19.0 11.1 23.1 20.0 16.7 19.6 
23F 20.0 0.0 10.5 4.8 11.1 7.7 10.0 0.0 8.0 
ADDITIONAL PCV13 
SEROTYPES 
         
3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.3 0.9 
6A 0.0 7.7 10.5 0.0 0.0 0.0 0.0 0.0 2.7 
19A 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.7 1.8 
OTHER SEROTYPES 
         
15B/C 13.3 0.0 0.0 0.0 11.1 0.0 0.0 16.7 4.5 
10A 0.0 0.0 5.3 4.8 11.1 7.7 0.0 0.0 3.6 
8 0.0 0.0 0.0 0.0 0.0 7.7 0.0 8.3 1.8 
22F 6.7 0.0 0.0 0.0 0.0 0.0 0.0 8.3 1.8 
11A 0.0 0.0 0.0 4.8 0.0 0.0 0.0 0.0 0.9 
12F 0.0 0.0 0.0 0.0 11.1 0.0 0.0 0.0 0.9 
33F 0.0 0.0 0.0 0.0 0.0 0.0 10.0 0.0 0.9 
9N 0.0 0.0 0.0 0.0 0.0 0.0 10.0 0.0 0.9 
27 0.0 0.0 0.0 0.0 0.0 0.0 10.0 0.0 0.9 
38 0.0 0.0 0.0 0.0 0.0 0.0 10.0 0.0 0.9 
23B 0.0 0.0 0.0 0.0 0.0 7.7 0.0 0.0 0.9 
24F 0.0 0.0 0.0 0.0 0.0 7.7 0.0 0.0 0.9 
35F 0.0 0.0 0.0 0.0 11.1 0.0 0.0 0.0 0.9 
PERCENTAGE OF ALL 
ISOLATES 
         
PCV10 SEROTYPES 80.0 92.3 84.2 90.5 55.6 69.2 60.0 41.7 75.0 
NON-PCV10 SEROTYPES 20.0 7.7 15.8 9.5 44.4 30.8 40.0 58.3 25.0 
PCV13 SEROTYPES 80.0 100.0 94.7 90.5 55.6 69.2 60.0 66.7 80.4 
PCV13-PCV10 SEROTYPES 0.0 7.7 10.5 0.0 0.0 0.0 0.0 25.0 5.4 
NON-PCV13 SEROTYPES 20.0 0.0 5.3 9.5 44.4 30.8 40.0 33.3 19.6 
PPSV23 SEROTYPES 100.0 92.3 89.5 100.0 88.9 84.6 80.0 100.0 92.9 
PPSV23 UNIQUE 
SEROTYPES  
20.0 0.0 5.3 9.5 33.3 15.4 20.0 33.3 15.2 
NON-PPSV23 SEROTYPES 0.0 0.0 0.0 0.0 11.1 15.4 20.0 0.0 4.5 
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Table 3. Serotypes distribution (%) of pneumococcal meningitis isolates among persons ≥5 years of 
age reported to the NIPH-NIH, 2008-2015, Poland 
 
 
2008 2009 2010 2011 2012 2013 2014 2015 2008-2015 
NO. OF CASES REPORTED TO 
THE NIP-NIH 
88 113 106 126 98 161 134 160 986 
NO. OF ISOLATES (%) SENT 
TO NRCBM AND SEROTYPED 
37 (42) 66 (58) 66 (62) 59 (47) 57 (58) 96 (60) 90 (67) 93 (58) 564 (57) 
NO. OF DIFFERENT 
SEROTYPES 
20 31 26 28 21 32 28 31 49 
SIMPSON D' INDEX 0.961 0.962 0.947 0.943 0.949 0.960 0.943 0.963 0.954 
PCV10/PCV13 SEROTYPES 
         
1 0.0 0.0 1.5 1.7 0.0 2.1 1.1 2.2 1.2 
4 5.4 6.1 7.6 3.4 7.0 6.3 6.7 4.3 5.9 
5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
6B 5.4 1.5 3.0 6.8 3.5 4.2 5.6 2.2 3.9 
7F 2.7 0.0 1.5 3.4 0.0 2.1 5.6 0.0 2.0 
9V 8.1 3.0 3.0 1.7 1.8 5.2 1.1 3.2 3.2 
14 8.1 6.1 9.1 3.4 5.3 5.2 6.7 6.5 6.2 
18C 2.7 6.1 7.6 3.4 8.8 5.2 1.1 2.2 4.4 
19F 10.8 3.0 13.6 6.8 10.5 7.3 5.6 6.5 7.6 
23F 5.4 3.0 7.6 5.1 8.8 6.3 3.3 5.4 5.5 
ADDITIONAL PCV13 
SEROTYPES 
         
3 10.8 10.6 10.6 20.3 12.3 9.4 17.8 8.6 12.4 
6A 0.0 1.5 1.5 0.0 1.8 2.1 0.0 2.2 1.2 
19A 2.7 1.5 1.5 6.8 3.5 8.3 6.7 4.3 4.8 
OTHER SEROTYPES 
         
8 8.1 1.5 3.0 1.7 5.3 2.1 2.2 5.4 3.4 
10A 5.4 3.0 3.0 0.0 5.3 1.0 2.2 7.5 3.4 
22F 0.0 1.5 3.0 3.4 7.0 1.0 4.4 5.4 3.4 
9N 2.7 4.5 1.5 1.7 1.8 4.2 2.2 4.3 3.0 
11A 2.7 3.0 6.1 3.4 0.0 3.1 3.3 1.1 2.8 
15B/C 5.4 3.0 0.0 5.1 3.5 5.2 0.0 2.2 2.8 
12F 2.7 12.1 0.0 1.7 1.8 1.0 1.1 2.2 2.7 
17F 0.0 1.5 0.0 1.7 3.5 0.0 0.0 0.0 0.7 
33F 0.0 0.0 0.0 1.7 1.8 0.0 1.1 0.0 0.5 
20 2.7 3.0 1.5 0.0 3.5 0.0 2.2 0.0 1.4 
2 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.2 
23A 2.7 1.5 0.0 0.0 0.0 3.1 3.3 5.4 2.3 
23B 0.0 0.0 0.0 0.0 0.0 2.1 5.6 5.4 2.1 
6C 0.0 3.0 0.0 1.7 0.0 1.0 3.3 2.2 1.6 
15A 0.0 1.5 1.5 1.7 1.8 1.0 1.1 1.1 1.2 
6A 0.0 1.5 1.5 0.0 1.8 2.1 0.0 2.2 1.2 
31 0.0 3.0 0.0 1.7 0.0 1.0 0.0 1.1 0.9 
OTHER** 5.4 12.1 10.6 11.9 0.0 8.3 6.7 7.5 8.0 
PERCENTAGE OF ALL 
ISOLATES 
         
PCV10 SEROTYPES 48.6 28.8 54.5 35.6 45.6 43.8 36.7 32.3 39.9 
NON-PCV10 SEROTYPES 51.4 71.2 45.5 64.4 54.4 56.3 63.3 67.7 60.1 
PCV13 SEROTYPES 62.2 42.4 68.2 62.7 63.2 63.5 61.1 47.3 58.3 
PCV13-10 SEROTYPES 13.5 13.6 13.6 27.1 17.5 19.8 24.4 15.1 18.4 
NON-PCV13 SEROTYPES 37.8 57.6 31.8 37.3 36.8 36.5 38.9 52.7 41.7 
PPSV23 SEROTYPES 91.9 75.8 84.8 83.1 94.7 79.2 80.0 73.1 81.4 
PPSV23 UNIQUE SEROTYPES 29.7 34.8 18.2 20.3 33.3 17.7 18.9 28.0 24.3 
NON-PPSV23 SEROTYPES 8.1 24.2 15.2 16.9 5.3 20.8 20.0 26.9 18.6 
 
**Serotypes other than presented in the table, that occurred less than 10 times in 2005-2015 in Poland. Non-typeable 
isolates (n=4) were included. 
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Fig. 1 Reported rate of pneumococcal meningitis by district, Poland, 2005-2015 
 
*1- Dolnośląskie, 2- Kujawsko-pomorskie, 3- Lubelskie, 4- Lubuskie, 5- Łódzkie, 6- Małopolskie, 7- Mazowieckie, 8- Opolskie,  
9- Podkarpackie, 10- Podlaskie, 11- Pomorskie, 12- Śląskie, 13- Świętokrzyskie, 14- Warmińsko-mazurskie, 15- Wielkopolskie,  
16- Zachodniopomorskie 
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